Numinus and MAPS to Collaborate on MDMA Trial for PTSD

by Aya Gonzalez

Dec 03, 2020

Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding non-profit association dedicated to the study of psychedelics in a first-of-its-kind clinical trial on MDMA.

Numinus has signed a collaboration agreement with the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of MAPS. Together they will seek approval to undertake a single-arm, open-label, compassionate access trial using MDMA-assisted psychotherapy for patients who are suffering from post-traumatic stress disorder (PTSD).

Click here to read more.

We want to connect with you!

Sign up here so we can keep in touch.